newsfilter
← Latest News
Business Wire·

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Summit is Conducting HARMONi-7 in Patients with PD-L1 High-Expressing NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the